Head to Head Analysis: FluoroPharma Medical (OTCMKTS:FPMI) & Zynex (NASDAQ:ZYXI)

Zynex (NASDAQ:ZYXI) and FluoroPharma Medical (OTCMKTS:FPMI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Earnings and Valuation

This table compares Zynex and FluoroPharma Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20 million	0.04	$2.99 million	($2.43)	-0.05
FluoroPharma Medical	N/A	N/A	N/A	N/A	N/A

Zynex has higher revenue and earnings than FluoroPharma Medical.

Profitability

This table compares Zynex and FluoroPharma Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
FluoroPharma Medical	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations for Zynex and FluoroPharma Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1	2	1	0	2.00
FluoroPharma Medical	0	0	0	0	0.00

Zynex currently has a consensus price target of $4.90, indicating a potential upside of 3,820.00%. Given Zynex’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Zynex is more favorable than FluoroPharma Medical.

Risk & Volatility

Zynex has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, FluoroPharma Medical has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Insider & Institutional Ownership

29.7% of Zynex shares are held by institutional investors. 49.3% of Zynex shares are held by company insiders. Comparatively, 36.9% of FluoroPharma Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Zynex beats FluoroPharma Medical on 7 of the 10 factors compared between the two stocks.

About Zynex

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

About FluoroPharma Medical

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.